BSECompany Update5d ago · 27 Jul 2026, 07:26 pm
Senores Pharmaceuticals Limited has informed the Exchange regarding Audio recording of Earnings Conference Call for the quarter ended June 30, 2026
Senores Pharmaceuticals Ltd · 544319
✦ AI SummaryResults
Senores Pharmaceuticals Ltd has informed the BSE regarding the audio recording of its earnings conference call for the quarter ended June 30, 2026, which is available on its website.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment6/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Senores Pharmaceuticals Ltd - 544319 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Attachments (1)
📄pdf
Download →
fc65bd15-2fb4-400f-989b-480ae838c0bc.pdf
View document text
Date:
July 27, 2026
To, To,
Sr. General Manager Sr. General Manager
BSE Limited National Stock Exchange of India Limited
Listing Department Listing Department
Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G
Dalal Street Bandra Kurla Complex
Mumbai – 400 001 Bandra (E), Mumbai – 400 051
BSE Scrip Code: 544319 NSE Symbol: SENORES
Sub.: Audio recording of Earnings Conference Call for the quarter ended June 30, 2026
Dear Sir/Madam,
In compliance with Regulations 30 and 46 of the Securities and Exchange Board of India (Listing Obligations and
Disclosure Requirements) Regulations, 2015, (w“eF ihnearnecbiya li nRfeosruml ttsh”a)t the Company had Earnings Conference Call
with several Analysts/Institutional Investors/Funds and other investors on the Unaudited Financial Results of the
Company for the quarter ended June 30, 2026 on July 27, 2026.
The audio recording of said Earnings Conference Call of the Company held today i.e., Monday, July 27, 2026 is
available on the website of the Company and can be accessed at the weblink:
https://senorespharma.com/investor-meet/.
No Unpublished Price Sensitive Information was shared/discussed by the Company during the Earnings
Conference Call.
You are requested to take the same on record.
TFohra nSkeinnogr yeosu P. harmaceuticals Limited
Deval Rajnikant Shah
Whole Time Director & CFO
DIN: 00332722
Senores Pharmaceuticals Limited
1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India
P: +91 79 2999 9857 | E: info@senorespharma.com
W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263